Clidinium Bromide

Clidinium Bromide (CAS No.: 3485-62-9) is a synthetic quaternary ammonium anticholinergic compound in the antimuscarinic pharmacology class, broadly categorized for gastrointestinal neuropharmacology and smooth muscle function research, where it is used as a tool molecule to study cholinergic regulation of secretory and motility processes. Mechanistically, it acts as a muscarinic acetylcholine receptor antagonist at postganglionic parasympathetic neuroeffector sites, thereby attenuating receptor coupled signaling that normally promotes glandular secretion and contractile tone, including canonical G protein mediated phospholipase C inositol phosphate calcium mobilization pathways associated with muscarinic receptor activation in peripheral tissues. In experimental systems, reported pharmacological behavior is consistent with antimuscarinic inhibition observed from nanomolar to micromolar concentration ranges depending on receptor subtype context, assay format, and tissue preparation, while precise potency metrics can vary across literature sources and should be determined under standardized laboratory conditions for each study design. In biomedical research workflows, this agent is commonly applied in receptor pharmacology assays, ex vivo smooth muscle contraction models, and preclinical studies of gastrointestinal spasm and secretory physiology, and it is also used as a reference comparator in anticholinergic drug screening panels to benchmark pathway modulation and functional antagonism; the concentrations or doses used in experiments typically depend on specific experimental designs and research objectives.